| Value of Optic Nerve MRI in Multiple Sclerosis Clinical Management: A MAGNIMS Position Paper and Future Perspectives J Sastre-Garriga, A Vidal-Jordana, AT Toosy, C Enzinger, C Granziera, ... Neurology 103 (3), e209677, 2024 | | 2024 |
| Serum biomarkers at disease onset for personalized therapy in multiple sclerosis E Monreal, JI Fernández-Velasco, R Álvarez-Lafuente, ... Brain, awae260, 2024 | | 2024 |
| XVI Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2023 (II) O Fernández, X Montalbán, E Agüera, Y Aladro, A Alonso, R Arroyo, ... Revista de neurologia 79 (2), 51-66, 2024 | | 2024 |
| XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (II) O Fernández, X Montalbán, E Agüera, Y Aladro, A Alonso, R Arroyo, ... Revista de neurologia 79 (2), 51-66, 2024 | | 2024 |
| XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (I) O Fernández, X Montalbán, E Agüera, Y Aladro, A Alonso, R Arroyo, ... Revista de Neurologia 79 (1), 21-29, 2024 | | 2024 |
| Global and regional deep learning models for multiple sclerosis stratification from MRI L Coll, D Pareto, P Carbonell‐Mirabent, Á Cobo‐Calvo, G Arrambide, ... Journal of Magnetic Resonance Imaging 60 (1), 258-267, 2024 | 2 | 2024 |
| Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis JD Lunemann, H Hegen, LM Villar, K Rejdak, A Sao-Aviles, ... Neurology: Neuroimmunology & Neuroinflammation 11 (4), e200270, 2024 | | 2024 |
| The global patient-reported outcomes for multiple sclerosis initiative: bridging the gap between clinical research and care–updates at the 2023 plenary event P Zaratin, S Samadzadeh, M Seferoğlu, V Ricigliano, J dos Santos Silva, ... Frontiers in Neurology 15, 1407257, 2024 | | 2024 |
| IL-6 Inhibition as a Therapeutic Target in Aged Experimental Autoimmune Encephalomyelitis M Dema Etxezarreta, H Eixarch, M Castillo Juárez, C Espejo, ... MDPI, 2024 | | 2024 |
| IL-6 Inhibition as a Therapeutic Target in Aged Experimental Autoimmune Encephalomyelitis M Dema, H Eixarch, M Castillo, X Montalban, C Espejo International Journal of Molecular Sciences 25 (12), 6732, 2024 | | 2024 |
| Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis–From “The Big Idea” to “The Perfect Crime”? C Krogias, M Clanet, G Comi, R Gold, GL Lenzi, X Montalban, ... Brain, 2024 | 1 | 2024 |
| Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis RJ Fox, BAC Cree, J de Sèze, R Gold, HP Hartung, D Jeffery, L Kappos, ... Neurology 102 (9), e209357, 2024 | 3 | 2024 |
| Artificial intelligence applied to MRI data to tackle key challenges in multiple sclerosis S Collorone, L Coll, M Lorenzi, X Lladó, J Sastre-Garriga, M Tintoré, ... Multiple Sclerosis Journal, 13524585241249422, 2024 | 2 | 2024 |
| Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial L Kappos, G Edan, MS Freedman, HP Hartung, X Montalbán, F Barkhof, ... Journal of Neurology, 1-11, 2024 | | 2024 |
| Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis N Fissolo, P Benkert, J Sastre-Garriga, N Mongay-Ochoa, ... Journal of Neurology, Neurosurgery & Psychiatry 95 (5), 410-418, 2024 | 4 | 2024 |
| Longer-term (Up to 6 Years) Efficacy of Ofatumumab in People with Recently Diagnosed and Treatment-naive Relapsing Multiple Sclerosis (S31. 003) G Pardo, S Hauser, A Bar-Or, R Gold, X Montalban, J Cohen, ... Neurology 102 (17_supplement_1), 6149, 2024 | | 2024 |
| Relapse-associated Worsening and Progression-independent Relapse Activity in Ozanimod-treated Participants with Relapsing Multiple Sclerosis from the RADIANCE and DAYBREAK … M Filippi, J Riolo, J Cohen, HP Hartung, X Montalban, S Meuth, ... Neurology 102 (17_supplement_1), 3117, 2024 | | 2024 |
| Outcomes of COVID-19 in Ofatumumab-treated Patients with RMS: Data from the ALITHIOS Open-label Extension Study (P1-6.010) I Boer, B Cree, H Wiendl, A Cross, S Delgado, M Habek, N Khachanova, ... Neurology 102 (17_supplement_1), 3047, 2024 | | 2024 |
| Prognostic Value of On-treatment Serum Neurofilament Light Chain for New or Enlarging T2 Lesions in People with Relapsing Multiple Sclerosis: Pooled Analysis of the ASCLEPIOS I … T Leist, S Hauser, T Derfuss, H Wiendl, D Arnold, X Montalban, A Bhatt, ... Neurology 102 (17_supplement_1), 5251, 2024 | | 2024 |
| Safety of Remibrutinib Across Immune-mediated Diseases Supports Development in Multiple Sclerosis (P8-6.015) B Kieseier, X Montalban, M Williams, L Airas, S Saini, M Hide, G Sussman, ... Neurology 102 (17_supplement_1), 3084, 2024 | | 2024 |
